相关实验视频

Updated: Jan 18, 2026

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

作为一个新的平台来预测AAV基因疗法的疗效,iPSC-肝细胞有机体

Estelle Berreur¹, Giacomo Lazzaroni¹, Cyrill Roth²

¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.

Molecular therapy. Methods & clinical development

|September 10, 2025

概括

诱导的多能干细胞衍生肝脏器官有效预测腺相关病毒 (AAV) 基因治疗载体的性能. 这项研究评估了八种AAV血清型,发现AAV6和AAV8在体外没有引起肝毒性的情况下是最有效的.

科学领域:

基因治疗基因治疗
肝病学肝病学是一种肝病学.
干细胞生物学干细胞生物学

背景情况:

腺相关病毒 (AAV) 载体对于基因疗法至关重要,特别是针对肝脏的治疗.
预测人类特异性转导效率和AAV载体的肝毒性仍然是一个重大挑战.
可靠的体外模型对于弥合临床前研究和临床基因治疗应用之间的差距至关重要.

研究的目的:

在多个诱导多能干干细胞 (iPSC) 衍生的肝细胞器官捐赠者中比较评估腺相关病毒 (AAV) 转导效率和肝毒性.
建立一个新的平台来评估人类肝脏模型中的AAV载体性能.
为了研究AAV转导在不同人类肝脏模型和AAV血清型的变异性.

主要方法:

测试八种AAV血清型 (AAV1-6,AAV8,AAV9) 的转导效率和肝毒性,在iPSC衍生的肝脏器官和肝细胞系 (HepG2,HepaRG) 中.
通过阿斯巴酸胺转移酶 (AST) 释放和细胞活力测量来评估肝毒性.
在不同的有机体捐赠者和细胞系中对AAV载体性能进行比较分析.

主要成果:

AAV6和AAV8在iPSC衍生的肝脏器官中表现出最高的转导效率,而AAV4和AAV5表现出最低的效率.
在不同的有机体捐赠者和肝细胞系中观察到显著的转导变异性.
在实验室中没有检测到显著的肝毒性,这表明在测试条件下,AAVs不会引起立即的肝损伤.

结论:

从iPSC衍生的肝细胞有机体作为一种新且有效的工具,用于在体外预测AAV转导效率和安全.
这种模型系统有可能改善基于AAV的基因疗法的转化到临床应用中.
该研究强调了供体变异性和模型选择在评估肝脏向基因治疗的AAV载体性能方面的重要性.

关键词:

在AAV血清型的AAV血清型中.在 AAV 传导中,AAV 传导 AAV 矢量是 AAV 的矢量.这是一种HepG2型肝炎.这就是HepaRGG.肝细胞肝细胞基因治疗的基因疗法这就是 iPSC 的意义.在体外模型模型中的体外模型.肝脏肝脏肝脏肝脏肝脏肝脏有机生物有机物

更多相关视频

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

相关概念视频

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...